Company Filing History:
Years Active: 2003
Title: Mark Aaron Emalfrab: Innovator in Filamentous Fungal Transformation Systems
Introduction
Mark Aaron Emalfrab is a notable inventor based in Jupiter, FL (US). He has made significant contributions to the field of biotechnology, particularly in the development of transformation systems for filamentous fungal hosts. His innovative work focuses on expressing and secreting heterologous proteins or polypeptides, which has important implications for various industries.
Latest Patents
Emalfrab holds a patent for a novel transformation system in the field of filamentous fungal hosts. This system is designed for expressing and secreting heterologous proteins or polypeptides. The invention outlines a process for producing large amounts of polypeptide or protein in an economical manner. The system comprises a transformed or transfected fungal strain of the genus Chrysosporium, including its mutants or derivatives. Additionally, it covers transformants containing Chrysosporium coding sequences, as well as expression-regulating sequences of Chrysosporium genes. The patent also introduces novel fungal enzymes along with their encoding sequences and expression-regulating sequences.
Career Highlights
Mark Aaron Emalfrab is associated with Dyadic International, Inc., where he applies his expertise in biotechnology. His work at the company has been instrumental in advancing the understanding and application of fungal transformation systems. Emalfrab's innovative approach has positioned him as a key figure in the field.
Collaborations
Emalfrab has collaborated with notable colleagues, including Richard Paul Burlingame and Philip Terry Olson. These partnerships have contributed to the development of his patented technologies and have fostered a collaborative environment for innovation.
Conclusion
Mark Aaron Emalfrab is a distinguished inventor whose work in filamentous fungal transformation systems has the potential to revolutionize the production of proteins and polypeptides. His contributions to biotechnology continue to pave the way for advancements in the field.